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This issue of Therapeutics and Clinical Risk Management contains interesting reviews 
on rheumatoid arthritis (RA), ulcerative colitis (UC) and steroid-resistant asthma 
all of which are distressing chronic inﬂ  ammatory conditions of unclear etiology. 
Rheumatoid arthritis (RA) is a prevalent condition whose clinical sequelae can result 
in signiﬁ  cant reductions in functional capacity and quality of life with considerable 
attendant debilitating impact upon psychological health. Despite recent therapeutic 
advances, a number of challenges remain: only a percentage of patients will respond 
to the disease-modifying antirheumatic drugs (DMARDs); toxicity and/or resistance 
dictate that another sub-group requires combinations of DMARDs and the antitumor 
necrosis factor-α (TNF-α) agents. Poor disease control in RA leads to joint pain and 
deformity with consequent functional impairment and loss of independence, patients 
may also experience signiﬁ  cant systemic illness including nodules, vasculitis, pulmo-
nary ﬁ  brosis and nerve entrapment. Among the new and more powerful DMARDs 
that have recently become available inﬂ  iximab (IFX), a chimeric TNF-α monoclonal 
antibody (mAb), has shown great promise. Levels of TNF-α, a potent pro-inﬂ  ammatory 
cytokine, are elevated in the sites of inﬂ  ammation associated with RA, for example 
in the synovial ﬂ  uid and sera of patients with active disease. TNF-α acts as a potent 
osteogenic cytokine and is thought to be the central mediator of joint destruction in 
rheumatoid arthritis. However, as Sophie Martin Du Pan and colleagues (2007) point 
out in the current issue of TCRM, the use of the more expensive biologic agents such 
as IFX tend to be limited to patients who have failed one or more traditional approaches 
to treatment on cost grounds. As this effectively eliminates these agents from the man-
agement of early RA, these authors have examined the evidence in support of the use 
of IFX in early RA as this approach may be more effective than treatment later in the 
course of the disease. They therefore conducted a systematic review of the literature 
and performed a meta-analysis of the RA bone erosion score (vdH Sharp Score) and 
RA functional disability score in randomized clinical trials that compared treatment 
with methotrexate-IFX (MTX-IFX) with methotrexate-placebo (MTX-placebo). The 
authors report that there is no evidence to support the superiority of MTX-IFX over 
MTX in combination with traditional disease-modifying antirheumatic drugs but they 
recommend that IFX should be used in those early RA patients demonstrating signs 
of aggressive disease, such as a limited response to MTX alone or the presence of 
rapidly progressing erosions.
Ulcerative colitis is a chronic inﬂ  ammatory condition of the large bowel leading to 
abdominal pain, diarrhea and in some cases other systemic features such as fever and 
weight loss. The underlying cause of UC remains elusive although current thinking 
favours defects in the mucosal immune system and/or epithelial integrity resulting in 
an abnormal inﬂ  ammatory response to normal intestinal microﬂ  ora. Rafﬁ   Karagozian 
and Robert Burakoff (2007) have provided an excellent review on the eitiology, 
pathogenesis and clinical course of UC. They detail current treatment modalities for 
UC with an emphasis on mesalamine a 5-aminosalicylate; these are newer formulations 
of salicylates-based drugs with fewer side-effects. The authors rate mesalamine as 
an excellent ﬁ  rst-line therapy for treatment of mild to moderate UC and also for the 
maintenance of remission. They further emphasise the importance of maximization of 
local mucosal concentration of mesalamine by utilizing the most appropriate delivery 
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formulation. Furthermore, newer formulations have been 
developed which will require less frequent dosing and this 
should aid compliance. However, as UC is a chronic remitting 
active inﬂ  ammatory condition, the majority of patients are 
likely to require life-long therapy.
Asthma is another chronic inﬂ  ammatory condition requir-
ing life-long therapy for the majority of patients. Antiinﬂ  am-
matory therapy in asthma is largely reliant on glucocorticoids 
(GC) – particularly in their inhaled form – with or without 
the addition of short- or long-acting bronchodilators. The 
symptoms of most asthmatics are satisfactorily controlled by 
regular use of inhaled GC. However, their use often raises 
concerns with respect to compliance. There is also increasing 
evidence that long-term use of inhaled GC, especially in high 
doses, can cause systemic adverse effects, including adrenal 
suppression, reduced growth and reduced bone-mineral density, 
as well as local side effects such as dysphonia. Moreover, 
a sub-group of asthmatic patients responds poorly or not at 
all to high-dose inhaled or systemic GC treatment. Although 
the numbers of these patients are small they do require a 
disproportionate amount of scarce resources to treat their 
condition. As there are few alternative treatments, these 
patients can be difﬁ  cult to treat and may require frequent 
hospitalisation. Their quality of like is also severely impaired 
by both symptoms and the toxic effects of high-dose systemic 
GC. Thus a timely review from Christopher Corrigan (2007) 
comprehensively addresses the current status of our under-
standing of the key clinical issues surrounding this important 
condition. In particular the difﬁ  culties of reliably identifying 
these patients is emphasised in addition to the thorny prob-
lem of non-compliance by patients in relation to inhaled GC 
therapy. The molecular mechanisms by which for GC exert 
their actions are described together with potential defects in 
these complex processes thought to be responsible for steroid 
resistance in asthma. A number of alternatives to GC therapy 
are discussed but the majority of these are far from satisfac-
tory. The author concludes that the identiﬁ  cation of reliable 
biomarkers for airway inﬂ  ammation in asthma are required 
to permit GC responsiveness to be assessed accurately and 
objectively in the short and long term.
The cysteinyl leukotrienes (LTC4, LTD4, LTE4) induce 
bronchoconstriction and are highly potent mediators of air-
way inﬂ  ammation in asthma. The cysteinyl leukotriene recep-
tor antagonists were the ﬁ  rst new class of antiasthma drugs to 
be introduced in the last 30 years and are now an established 
part of the treatment of adult asthma. Overall, they are less 
effective than inhaled corticosteroids but some patients show 
a striking improvement and a corticosteroid-sparing effect 
has been demonstrated. Three drugs of this class are in use 
at present: zaﬁ  rlukast, pranlukast, and montelukast. All three 
are speciﬁ  cally active against the cysteinyl leuko-trienes by 
blocking their receptor, CysLT1. Thus, to continue with the 
asthma theme in the current issue, Koray Harmanci (2007) 
has provided a detailed review of the use of montelukast in 
childhood asthma. Overall, it appears that montelukast is 
not suitable as monotherapy in mild and moderate-severe 
persistent asthma in children being inferior to inhaled corti-
costeroids. However, montelukast appears to be effective in 
exercise-induced and aspirin intolerant asthma in children 
and has the advantage of being administered orally rather 
than as inhaled therapy.
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